PA5-76870

antibody from Invitrogen Antibodies

Targeting: PHLDA2 BWR1C, HLDA2, IPL, TSSC3

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-76870

Provider

Invitrogen Antibodies

Product name

PHLDA2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Chaperone mediated detection of small molecule target binding in cells.

Cho KF, Ma TP, Rose CM, Kirkpatrick DS, Yu K, Blake RA
Nature communications 2020 Jan 23;11(1):465

---

Abundances of placental imprinted genes CDKN1C, PHLDA2 and IGF-2 are related to low birth weight and early catch-up growth in full-term infants born small for gestational age.

Xing Y, Liu H, Cui Y, Wang X, Tong X
PloS one 2019;14(6):e0218278

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of PHLDA2 in HeLa cells. Samples were incubated with PHLDA2 polyclonal antibody (Product # PA5-76870).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 4 Mass spectrometry-based proteomics identifies TAK-285 cellular protein targets. a Schematic illustration of experimental design for global proteomics profiling. MCF-7 neoHER2 cells were treated with DMSO, TAK-285 (100 nM or 1 uM), 17-AAG (1 µM), or pretreated with TAK-285 (100 nM or 1 uM), followed by 17-AAG (1 µM). 17-AAG treatment time is 8 h (for the 100 nM set) and 6 h (for the 1 uM set). b Volcano plot depicting the fold-change in protein abundance in MCF-7 neoHER2 cells treated with 17-AAG (8 h) relative to DMSO samples. Each circle represents an individual protein with the color representing protein class (kinase: red; others: blue). X-axis: log2 transformed ratio of the protein levels in the 17-AAG treated samples and the DMSO treated samples. Y-axis: -log10 transformed p-value (dotted lines indicate p = 0.05 and p = 0.01; two-tailed student's t -test). Density curves for the two protein groups are shown at the bottom. c Distribution of ratio changes between 17-AAG (8 h) and DMSO in protein groups: by protein function, HSP90-interaction, or HSP90 dependency ( p < 0.00001 (***)) by Welch two-sample t-test (box plots show minimum, first quartile, median, third quartile, and maximum). d , e Volcano plot showing the fold change in protein abundance in MCF-7 neoHER2 cells treated with a combination of 17-AAG and TAK-285, 100 nM d or 1 uM e relative to 17-AAG only samples. Annotated proteins (and alternative gene names) include: ERBB2 (H